Frederick A Zeiler1, Kaitlin J Zeiler2, Jeanne Teitelbaum2, Lawrence M Gillman3, Michael West1. 1. 1Section of Neurosurgery,Department of Surgery,University of Manitoba,Winnipeg,Canada. 2. 2Section of Neurocritical Care,Montreal Neurological Institute,McGill,Montreal,Canada. 3. 4Section of Critical Care Medicine,Department of Medicine,University of Manitoba,Winnipeg,Canada.
Abstract
BACKGROUND: Our goal was to perform a systematic review of the literature on the use of modern inhalational anesthetic agents for refractory status epilepticus and their impact on seizure control. METHODS: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (inception to March 2014), reference lists of relevant articles, and gray literature were searched. The strength of evidence was adjudicated using both the Oxford and Grading of Recommendation Assessment Development and Education methodology by two independent reviewers. RESULTS: Overall, 19 studies were identified, with 16 manuscripts and 3 meeting abstracts. A total of 46 patients were treated. Adult (n=28) and pediatric patients (n=18) displayed 92.9% and 94.4% seizure control with treatment, respectively. Isoflurane was used in the majority of cases. Hypotension was the only complication described. CONCLUSIONS: Oxford level 4, Grading of Recommendation Assessment Development and Education D evidence exists to support the use of isoflurane in refractory status epilepticus to obtain burst suppression. Insufficient data exist to comment on the efficacy of desflurane and xenon at this time.
BACKGROUND: Our goal was to perform a systematic review of the literature on the use of modern inhalational anesthetic agents for refractory status epilepticus and their impact on seizure control. METHODS: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (inception to March 2014), reference lists of relevant articles, and gray literature were searched. The strength of evidence was adjudicated using both the Oxford and Grading of Recommendation Assessment Development and Education methodology by two independent reviewers. RESULTS: Overall, 19 studies were identified, with 16 manuscripts and 3 meeting abstracts. A total of 46 patients were treated. Adult (n=28) and pediatric patients (n=18) displayed 92.9% and 94.4% seizure control with treatment, respectively. Isoflurane was used in the majority of cases. Hypotension was the only complication described. CONCLUSIONS: Oxford level 4, Grading of Recommendation Assessment Development and Education D evidence exists to support the use of isoflurane in refractory status epilepticus to obtain burst suppression. Insufficient data exist to comment on the efficacy of desflurane and xenon at this time.
Authors: Kristin M Ikeda; Robert Connors; Donald H Lee; Alexander G Khandji; Jan Claassen; G Bryan Young Journal: Neurocrit Care Date: 2017-06 Impact factor: 3.210
Authors: Barbara Schultz; Terence Krauß; Maren Schmidt; Michael Schultz; Andrea Schneider; Olaf Wiesner; Julius J Schmidt; Klaus Stahl; Sascha David; Marius M Hoeper; Markus Busch Journal: Front Med (Lausanne) Date: 2021-03-26